Abstract:Background/Aims: The purpose of this study was to probe the clinico-pathological significance and the underlying mechanism of miR-30d-5p expression in non-small cell lung cancer (NSCLC). Methods: We initially examined the level of miR-30d-5p expression in NSCLC and non-cancer tissues using RT-qPCR. Then, a series of validation analyses including a meta-analysis of data from microarray chips in Gene Expression Omnibus (GEO), data mining of the cancer genome atlas (TCGA) and an integrated meta-analysis incorporating GEO microarray chips, TCGA data, in-house RT-qPCR and literature studies were performed to examine the clinico-pathological value of miR-30d-5p expression in NSCLC. In vitro experiments were further conducted to investigate the impact of miR-30d-5p on NSCLC cell growth. The molecular mechanism by which miR-30d-5p regulates the pathogenesis of NSCLC was probed through a bioinformatics analysis of its target genes. Moreover, dual luciferase reporter assay was conducted to verify the targeting regulatory relationship between miR-30d-5p and CCNE2. Results: Based on results from RT-qPCR, GEO meta-analysis, TCGA data mining and the integrated meta-analysis incorporating GEO microarray chips, TCGA data, in-house RT-qPCR and literature studies, miR-30d-5p expression was decreased in NSCLC tissues, and patients with NSCLC who presented with lower miR-30d-5p expression tended to display an advanced clinical progression. Significant pathways including the Mucin type O-glycan biosynthesis pathway, cell cycle pathway and cysteine and methionine metabolism pathway (all P< 0.05) revealed potential roles of the target genes of miR-30d-5p in the oncogenesis of NSCLC. Results from in vitro experiments indicated that miR-30d-5p could attenuate proliferation and viability of NSCLC cells. Among the 12 identified hub genes, nine genes including E2F3, CCNE2, SKP2, CDK6, TFDP1, LDHA, GOT2, DNMT3B and ST6GALNAC1 were validated by Pearson’s correlation test and the human protein atlas (HPA) database as targets of miR-30d-5p with higher probability. Specifically, dual luciferase reporter assay confirmed that CCNE2 was directly targeted by miR-30d-5p. Conclusion: In summary, miR-30d-5p expression is decreased in NSCLC, and it might play the role as tumor suppressor in NSCLC by regulating target genes.

MicroRNA-30e Reduces Cell Growth and Enhances Drug Sensitivity to Gefitinib in Lung Carcinoma

miR-30 functions as a tumor suppressor by modulating CD90 in hepatocellular carcinoma

MicroRNA-302d Downregulates TGFBR2 Expression and Promotes Hepatocellular Carcinoma Growth and Invasion.

MiR-142-5p Reverses the Resistance to Gefitinib Through Targeting HOXD8 in Lung Cancer Cells.

MicroRNA-34a Overcomes HGF-mediated Gefitinib Resistance in EGFR Mutant Lung Cancer Cells Partly by Targeting MET.

MicroRNA-30e inhibits proliferation and invasion of non-small cell lung cancer via targeting SOX9

MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines

miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc

Expression Signature and Role of Mir-30D-5p in Non-Small Cell Lung Cancer: a Comprehensive Study Based on in Silico Analysis of Public Databases and in Vitro Experiments

MicroRNA-30d-5p Inhibits Tumour Cell Proliferation and Motility by Directly Targeting CCNE2 in Non-Small Cell Lung Cancer.

Increased MIR31HG Lncrna Expression Increases Gefitinib Resistance in Non-Small Cell Lung Cancer Cell Lines Through the EGFR/PI3K/AKT Signaling Pathway

microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation

Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer

MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines

miR-30b-5p inhibits cancer progression and enhances cisplatin sensitivity in lung cancer through targeting LRP8

MiRNA-200a Sensitizes Non-Small-cell Lung Cancer to EGFR-TKIs by Targeting FOXC1

Co-targeting of EGFR by Co-Expressed Mirna-193A-3p/−5p in Lung Cancer

MicroRNA-508-3p Regulates the Proliferation of Human Lung Cancer Cells by Targeting G1 to S Phase Transition 1 (GSPT1) Protein.

MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin

Microrna-137 Inhibits Tumor Growth And Sensitizes Chemosensitivity To Paclitaxel And Cisplatin In Lung Cancer

miR-30c plays diagnostic and prognostic roles and mediates epithelial–mesenchymal transition (EMT) and proliferation of gliomas by affecting Notch1